Riluzole

Riluzole is a pharmaceutical-grade active ingredient classified as a Glutamate Antagonist Neuroprotective Agent. Mediocon Inc supplies high-purity Riluzole API conforming to IP / BP / EP / USP specifications, manufactured in our GMP-certified facility in Aurangabad, Maharashtra, India.

Riluzole is the first and most established disease-modifying treatment for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. It works by inhibiting glutamate-mediated neurotoxicity, blocking sodium channels, and interfering with intracellular signaling cascades linked to glutamate receptor activation. Riluzole slows disease progression and extends patient survival.

Key Features

• High-purity pharmaceutical grade API
• IP/BP/EP/USP compliant
• Full CoA and MSDS documentation
• GMP certified manufacturing

Applications

• Amyotrophic lateral sclerosis (ALS/MND) treatment
• Neuroprotection in motor neuron diseases
• Huntington's disease (investigational use)
• Cerebellar ataxia management

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings